Furthermore, with the advent of new treatments such as Glucagon-Like Peptide-1 receptor agonists, which have demonstrated cardioprotective and metabolic benefits in population with diabetes, it remains unclear how these therapies may influence outcomes in SPKT versus DDKT recipients. This evidence concerns the gene GLP1R and diabetes mellitus.